KIWUMULO JOHN AUSTIN

Doubled customer reach, expanded key brand user base and unlocked institutional use of modern insulin hence driving greater growth of modern Insulin brands and contributing to the bigger region's business target by;

• Providing senior-level leadership in stakeholder engagement and access-oriented activities supporting diabetes care across Uganda.
• becoming a more trusted partner to public-sector institutions, teaching hospitals, and senior clinicians, supporting sustainable access to Novo Nordisk's insulin therapies
• Contributing to country level and regional strategy execution, aligning commercial objectives with access, compliance and business priorities.
• Maintain oversight of ethical promotion, governance and compliance in line with Novo Nordisk global and regional standards.

Key Achievements:

• Achieved an overall 126% Country business target performance
• Achieved 140% Novomix Flexpens target (2025).
• Sustained Uganda as a top performing country within ESA

Drove in-market business growth, sustained tender, elevated company brand image and unlocked modern insulin business opportunities by;

• Leading government, institutional, and key account engagement to support access to Novo Nordisk’s diabetes portfolio across Uganda.
• Working closely with public hospitals, Key institutions (JMS), Ministry of Health, and professional associations to facilitate product uptake and continuity of care.
• Supporting market shaping activities, including clinician education, access discussions, and value communication aligned with national treatment priorities.
• Got appointed as Local QPPV for Uganda, ensuring full compliance with safety reporting and regulatory requirements.
• Serving as compliance Ambassador for the East Africa Sales team, promoting ethical engagements, adherence to internal and external regulations.
• Acted as Support EA sales team trainer, building regional capabilities and supporting consistent execution across markets.

Key Achievements:

• East&South Africa SPA of the year 2015
• Human Insulin Sales Achievement Award 2018 - 110% target realization.
• Top performing Country Award 2020 - 120% annual target achievement.
• Human Insulin Flexpens ESA Achievement Award 2021 - 110% target achievement.
• Multichannel Customer Engagement & FFCE Regional Achievement Award 2023
• Top performing country Award (120% target realization) 2024
• Best Frontline Achievers Award (in Denmark) for best performing representative 2025

• Managed promotion and institutional uptake of anti-hypertensive and anti-diabetic portfolios.
• Supported brand entry into Hospitals and institutional accounts, contribution to improved patient access.
• Achieved significant commercial growth, increasing monthly business performance from UGX 70 million to UGX 300 million per month.
• Was recognized twice as Best Performing Medical Representative.

• Supported hospital entry and end-user engagement for maternal health products
• Represented the organization at medical conferences and media platforms to support product awareness and uptake.